Is pericardial effusion a negative prognostic marker? Meta-analysis of outcomes of pericardial effusion

Background The prognostic relevance and the prevalence of pericardial effusion in several diseases are not well established. The aim of this meta-analysis is to summarize the available evidence related to pericardial effusion prevalence and outcomes according to the cause. Methods Articles investigating the prognosis of pericardial effusion were identified by literature search. Twenty-three studies were finally included (17 022 patients). All-cause mortality was the primary end-point. Secondary end-point was the prevalence of pericardial effusion in most common diseases related to this clinical condition. Results The pooled prevalence of pericardial effusion was 19.5% [95% confidence interval (CI): 14.3–26]. After a mean follow-up of 36 ± 23 months, the risk of death was higher in pericardial effusion patients [hazard ratio (HR) 1.59, 95% CI 1.37–1.85, P < 0.0001]. Stratifying for the main disease, pericardial effusion is associated with unfavourable outcome in all available subgroups: pulmonary arterial hypertension HR 1.53 (95% CI: 1.22–1.92; P < 0.0001), chronic heart failure (CHF) HR 1.53 (95% CI: 1.22–1.92; P < 0.0001), myocardial infarction HR 2.65 (95% CI: 1.4–4.99; P = 0.003) and malignancies HR 1.75 (95% CI: 1.09–2.81, P = 0.021). The lack of data concerning the idiopathic pericardial effusion does not permit a secure risk assessment but the average incidence of mortality is 14.5% (95% CI: 7.7–25.6). Conclusion Pericardial effusion should be considered a marker of the severity of the underlying disease, whereas for idiopathic pericardial effusion the correlation with poor prognosis is less clear.

[1]  F. Edelmann,et al.  Chronic Heart Failure. , 2018, Deutsches Arzteblatt international.

[2]  H. Thiele,et al.  Effect of Pericardial Effusion Complicating ST-Elevation Myocardial Infarction as Predictor of Extensive Myocardial Damage and Prognosis. , 2015, The American journal of cardiology.

[3]  L. Sinak,et al.  Pericardial effusions in pulmonary arterial hypertension: characteristics, prognosis, and role of drainage. , 2013, Chest.

[4]  M. Humbert,et al.  Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. , 2013, Arthritis and rheumatism.

[5]  Y. Adler,et al.  Management of pericardial effusion. , 2013, European heart journal.

[6]  F. Ruschitzka,et al.  Haemodynamically irrelevant pericardial effusion is associated with increased mortality in patients with chronic heart failure. , 2013, European heart journal.

[7]  C. Hill,et al.  Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study , 2012, Arthritis Research & Therapy.

[8]  Mu Qin,et al.  Prognosis investigation in patients with chronic heart failure and pericardial effusion. , 2011, Chinese medical journal.

[9]  Y. Adler,et al.  Triage and management of pericardial effusion , 2010, Journal of Cardiovascular Medicine.

[10]  S. Khan,et al.  Frequency of pericardial effusion in patients with first myocardial infarction and its effects on in-hospital morbidity and mortality. , 2010, Journal of Ayub Medical College, Abbottabad : JAMC.

[11]  MassimoImazio,et al.  Indicators of Poor Prognosis of Acute Pericarditis , 2007 .

[12]  M. Emdin,et al.  Heart involvement and systemic sclerosis , 2005, Lupus.

[13]  N. Goodson,et al.  Cardiovascular involvement in rheumatoid arthritis , 2005, Lupus.

[14]  R. Shabetai Pericardial effusion: haemodynamic spectrum , 2004 .

[15]  M. Petri,et al.  Cardiac Involvement in Systemic Lupus Erythematosus , 2003 .

[16]  J. Seward,et al.  Outcomes of clinically significant idiopathic pericardial effusion requiring intervention , 2003 .

[17]  J. Cortadellas,et al.  Nature and progression of pericardial effusion in patients with a first myocardial infarction: relationship to age and free wall rupture. , 2002, American heart journal.

[18]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[19]  T. Miller,et al.  Cardiac involvement in systemic lupus erythematosus. , 1999, Mayo Clinic proceedings.

[20]  C. O'connor,et al.  Etiology of large pericardial effusions. , 1993, The American journal of medicine.

[21]  N. Schiller,et al.  Prognostic value of echocardiography in hospitalized patients with pericardial effusion. , 1992, The American journal of cardiology.

[22]  Jeroen J. Bax,et al.  The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS) , 2015 .

[23]  P. Heidenreich,et al.  A small pericardial effusion is a marker of increased mortality. , 2011, American heart journal.